You are here: Industry Insights > Eli Lilly

News List

Gilead, Galapagos’ filgotinib aces first phase 3, suggesting it can compete with AbbVie’s upadacitinib fiercebiotech
September 13, 2018
The placebo-adjusted figures are in line with those generated in late-phase trials of rival JAK drugs.
Key California lawmaker calls Eli Lilly’s behavior ‘disingenuous and offensive’ fiercepharma
August 15, 2018
Seven months after a controversial California law took effect requiring advance notice of planned price increases on prescription drugs, many pharmaceutical companies appear to be in compliance.
Eli Lilly expands cancer research alliance with Dana-Farber pharmaceutical-technology
August 01, 2018
Eli Lilly has extended its existing research collaboration with the Dana-Farber Cancer Institute to accelerate the development of new and advanced cancer treatments.
Ups and Downs! Pain Medication Tanezumab of Pfizer/Eli Lilly to See the Dawn amid Twists and Turns? Mr. Nanguo
August 01, 2018
Pfizer and Eli Lilly jointly announced recently that the Phase III trial of their anti-NGF antibody: tanezumab for the treatment of osteoarthritis (OA) pain met all the 3 endpoints.
Eli Lilly Q2 results: demand for new products fuels 9% revenue growth pharmaceutical-technology
July 30, 2018
Eli Lilly has published its revenue increased 9% to $6.4bn in the second quarter (Q2) of 2018, compared with $5.8bn in Q2 2017, due to a higher demand for new pharmaceutical products in the quarter.
Anima, Eli Lilly pen $1B-plus biobucks research pact fiercebiotech
July 26, 2018
Little-known private biotech Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seeks to work on the biotech’s translation inhibitors.
Eli Lilly's Taltz pads case for a shot at Novartis' Cosentyx in ankylosing spondylitis fiercepharma
June 29, 2018
Eli Lilly’s Taltz is already up against Novartis’ immunology blockbuster Cosentyx in psoriasis and psoriatic arthritis. Now, Lilly looks poised to challenge the Swiss drugmaker in a third indication, too.
Eli Lilly closes $1.6bn ARMO BioSciences acquisition pharmaceutical-technology
June 28, 2018
Eli Lilly has completed the acquisition of immuno-oncology company ARMO BioSciences in an all-cash deal valued at nearly $1.6bn.
AstraZeneca, Eli Lilly scrap Alzheimer’s treatment trial financialexpress
June 14, 2018
AstraZeneca and Eli Lilly have announced the ending of a large clinical trial of treatment for Alzheimer’s that they had been developing together.
Eli Lilly to buy Armo BioSciences for US$1.6B biospectrumasia
May 14, 2018
Lilly gives an offer of US$50 per share, which represents a premium of 68 percent to Armo's Wednesday close.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page